|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | BCLC策略:预后预测和治疗推荐2022版更新显示文摘2018版BCLC预后和治疗推荐策略发布后,肝细胞癌(简称HCC)的研究又取得了重大进展。本次更新基于肝癌各领域的研究进展结果。重点关注影响策略的重要研究进展。虽然近年的研究结果成绩斐然,但将其引入为临床医生和研究者提供行动依据的循证模型指南来说证据效力依然不够确切。本文对该问题进行分析,阐述了为HCC患者制定个体化治疗临床决策所需的批判性思维和专业知识。 | Reig M Forner A Rimola J Ferrer-Fabrega J Burrel M Garcia-Criado A Kelley RK Galle PR Mazzaferro V Salem R Sangro B Singal AG Vogel A Fuster J Ayuso C Bruix J 刘永凡(摘译) 崔笑(摘译) 耿小平(审校) | 2022 | 肝胆外科杂志2022，30，5： | 80 |
| 2 | 前庭性偏头痛:诊断标准——Barany学会及国际头痛学会共识文件显示文摘本文提供了前庭性偏头痛的诊断标准,由Barany学会前庭疾患分类委员会及国际头痛学会(IHS)偏头痛分类分委员会共同制定。分类包括前庭性偏头痛及很可能的前庭性偏头痛。与IHS的常规程序相同,前庭性偏头痛作为一种新分类,将首先出现在第3版国际头痛分类(ICHD-3)的附录中。若积累了进一步的证据,很可能的前庭性偏头痛也许会纳入更晚的ICHD版本中。前庭性偏头痛的诊断建立在反复发作的前庭症状、具有偏头痛病史、前庭症状与偏头痛症状间存在时间上的相关性,并排除其他可导致前庭症状的病因。符合前庭性偏头痛诊断的症状包括不同类型的眩晕及头部活动诱发的头晕伴恶心。症状的严重程度必须为中重度。急性发作的持续时间限于5 min^72 h的时间窗内。 | 华驾略 李焰生 Lempert T Olesen J Furman J Waterston J Seemungal B Carey J Bisdorff A Versino M Evers S Newman-Toker D | 2013 | 神经病学与神经康复学杂志2013，10，3： | 60 |
| 3 | Expression of the B7 - related molecule B7 - H1 by glioma cells: a potential mechanism of immune paralysis显示文摘Human glioblastoma is a highly lethal tumor that is known for its immune inhibitory capabilities.B7-homologue l(B7-H 1),a recently identified homologue of B7.1/2(CD80/86),has been described to exert costimulatoryand immune regulatory functions.We investigated the expression and the functional activity of B7-H 1 in humanglioma cells in vitro and in vivo.Although lacking B7.1/2(CD80/86),all 12 glioma cel1 1ines constitutivelyexpressed B7-H1 mRNA and protein.Exposure to IFN-gamma strongly enhanced B7-H 1 expression.Im- | Wintterle S Schreiner B Mitsdoerffer M Schneider D Chen Meyermann R Weller M Wiendl H | 2003 | 中国神经肿瘤杂志2003，1，4： | 37 |
| 4 | 心力衰竭的诊断与评估显示文摘心力衰竭是常见的临床综合征,以呼吸困难、疲乏和容量超负荷为特点,也可出现外周性水肿及肺部哕音。心力衰竭有较高的发病率和病死率,尤其是老年人。许多疾病,如冠状动脉疾病(CAD)、高血压、瓣膜性心脏病和糖尿病均可引起或导致慢性心力衰竭的失代偿。40%~50%的心力衰竭患者为左心室功能保留的舒张性心力衰竭,其总病死率与收缩性心力衰竭相似。初始评估包括病史、体检、胸部X线片、心电图(ECG)和实验室评估,以识别原因或诱因。心尖移位、第三心音和胸部X线片显示静脉充血或间质水肿常有助于识别心力衰竭。 | 周淑新 朱翠明 King M Kingery JE Casey B | 2012 | 中国全科医学2012，15，36： | 38 |
| 5 | AGNP精神科治疗药物监测共识指南:2011显示文摘治疗药物监测(Therapeutic drug monitoring,TDM),如通过定量测定血清或血浆药物浓度指导用药剂量优化,已经成为对患者进行精神药物治疗的很有价值的工具。在患者用药依从性难以判断、药物耐受性不佳、治疗剂量下无效以及可能存在药代动力学药物-药物相互作用等情况下,测定药物浓度是很有用的。在精神科,有可能明显获益于TDM的主要患者群体包括儿童、孕妇、老年患者、智力障碍患者、涉及司法的患者、已知或怀疑携带药代动力学相关基因变异的患者,以及合并躯体疾病影响药代动力学的患者。然而,只有将TDM充分整合到临床治疗过程中去,才能发挥其优化药物治疗的潜在优势。为了促进TDM的合理应用,神经精神药理学与药物精神病学协会(Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie,AGNP)的TDM专家组在2004年发表了精神药物治疗药物监测指南。之后,随着知识不断更新,又有许多可能需要进行TDM的新药上市。因此,本次更新将神经精神药物的种类扩展到了128种,并将其TDM必要性划分为从'强烈推荐'到'可能有用'的四个等级。经过大量细致且全面的文献检索与分门别类的汇总整理,将基于循证医学理念的'治疗参考浓度范围'和'剂量相关参考浓度范围'呈现给大家。本共识指南引入了'实验室警戒浓度'的新概念,即实验室需要马上告知治疗医生的药物浓度上限。本共识指南还给出了诸如药物作为细胞色素P450酶的底物和抑制剂的性质,代谢物与母药浓度比值的常见范围,以及与结果解释相关的内容,还提供了何时将TDM与遗传药理学检测相结合的建议。遵循本指南,有助于改善许多患者精神药物治疗的效果,特别是那些存在药代动力学异常的患者。TDM是一门交叉学科,有时针对看起来不一致的数据,需要多学科坦诚地讨论,只有这样,患者才能从这种合作中获益。 | Hiemke C Baumann P Bergemann N Conca A Dietmaier O Egberts K Fric M Gerlach M Greiner C Gründer G Haen E Havemann-Reinecke U Jaquenoud Sirot E Kirchherr H Laux G Lutz UC Messer T Müller MJ Pfuhlmann B Rambeck B Riederer P Schoppek B Stingl J Uhr M Ulrich S Waschgler R Zernig G 李文标(译) 果伟(译) 阮灿军(译) 贺静(译) 汤宜朗(审校) 王传跃(审校) | 2016 | 实用药物与临床2016，19，10： | 37 |
| 6 | Measurement of circulating levels of VEGF-A,-C,and -D and their receptors,VEGFR-1 and -2 in gastric adenocarcinoma显示文摘AIM: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A,-C,and -D,and their receptors,VEGFR-1 and -2 in gastric adenocarcinomas. METHODS: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. RESULTS: The serum levels of VEGF-A and its receptor,VEGFR-1,were signifi cantly higher in patients with gastric cancer than in healthy donors (t = 2.3,P = 0.02 and t = 4.2,P < 0.0001,respectively). In contrast,the serum levels of VEGF-D were signif icantly higher in control subjects than in patients (t = 2.9,P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis,advanced overall stage,tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival. CONCLUSION: Serum VEGF levels vary significantly in the same cohort of patients with variable clinico-pathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay. | Mansour S Al-Moundhri A Al-Shukaili M Al-Nabhani B Al-Bahrani IA Burney A Rizivi SS Ganguly | 2008 | World Journal of Gastroenterology2008，14，24： | 32 |
| 7 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 8 | 最新AD研究用诊断标准:IWG-2标准显示文摘在过去的8年中,国际工作组织(IWG)和美国国立老化研究院-阿尔茨海默协会(NIA-AA)建立了阿尔茨海默病(AD)诊断标准,它能更好地定义AD的临床表型,整合了生物标记物于诊断流程中,并覆盖了疾病的全程。本意见书充分地权衡了IWG标准的优缺点,建议改进诊断框架。依据这些改进,AD的诊断变得简单,只要有恰当的AD临床表型(典型或不典型)和与AD的病理相一致的病理生理学生物标志物出现。我们认为疾病的下游的定位性生物标志,如容积性磁共振成像(MRI)和氟脱氧葡萄糖-正电子发射型计算机断层成像(FDG-PET)等,适合更好地测量和监测疾病过程。本文还详述了非典型性AD、混合性AD和AD临床前期的特异诊断标准。 | 陈刚 曹雯炜 俞羚 糜建华 Dubois B Feldman HH Jacova C Hampel H Molinuevo JL Blennow K DeK osky ST Gauthier S Selkoe D Bateman R Cappa S Crutch S Engelborghs S Frisoni GB Fox NC Galasko D Habert MO Jicha GA Nordberg A Pasquier F Rabinovici G Robert P Rowe C Salloway S Sarazin M Epelbaum S de Souza LC Vellas B Visser PJ Schneider L Stern Y Scheltens P Cummings JL | 2014 | 神经病学与神经康复学杂志2014，11，3： | 31 |
| 9 | 囊性肾瘤、肾脏混合性上皮和间质肿瘤34例临床病理分析显示文摘 | Turbiner J Amin M B Humphrey P A 刘飞飞(摘译) 张仁亚(审校) | 2007 | 临床与实验病理学杂志2007，23，3： | 29 |
| 10 | 青藏东北缘早第三纪盆地充填的沉积型式及构造背景——以囊谦和下拉秀盆地为例显示文摘一系列中小型早第三纪红色盆地出露于青藏高原的东北缘 ,它们是在印度—欧亚板块碰撞过程中因陆壳变形和高原隆升产生的。典型早第三纪盆地的地质填图和详细的沉积学研究 ,及构造、沉积和岩浆热事件的综合分析表明 ,这些盆地具有两阶段构造—沉积特征 ,即早期受控于逆冲挤压背景 ,盆地接受底部冲积扇体系的粗碎屑岩段沉积 ,局部伴有岩浆活动 ;晚期受控于走滑—拉分背景 ,盆地充填湖泊—三角洲体系的含膏砂泥岩段夹薄层灰岩 ,并伴有广泛的岩浆作用。青藏东北缘早第三纪盆地在盆地构造格架、沉积层序结构、沉积物组成和岩浆活动等方面均存在明显的阶段性演化。盆地古水流统计和岩浆岩4 0 Ar/ 3 9Ar定年结果表明 ,青藏东北缘早第三纪盆地沉积物主要形成于始新世晚期—渐新世早期 (38~ 2 9Ma)。盆地沉积型式和岩浆活动受印度—欧亚板块碰撞早期逆冲挤压和走滑—拉分构造格局的控制。 | 周江羽 王江海 尹安 Spurlin M S Horton B K | 2002 | 沉积学报2002，20，1： | 30 |
| 11 | 美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病临床前阶段的定义显示文摘阿尔茨海默病(AD)的病理生理过程在痴呆诊断的多年前就开始了。这一长期的AD“临床前”阶段是治疗干预的关键机会,但需进一步阐明AD的病理级联过程和临床症状出现之间的联系。美国国立老化研究所和AD协会召集了一个国际工作组对AD生物标志物、流行病学和神经心理学的证据进行综述并提出建议,以确定能够预测由“正常”认知到轻度认知功能障碍(MCI)及AD痴呆的最佳预测指标。根据目前已有的主要科学证据,我们提出了一个概念性的框架和用于操作的研究标准,以通过纵向临床研究来验证和改进这些模型。这些建议仅用于研究目的,目前不涉及临床应用。我们希望这些建议能提供一个共识,以推进临床前AD的研究,最终推动更早期治疗干预的进展,使得一些疾病减缓药物的疗效发挥最大。 | Sperling RA Aisen PS Beckett LA Bennett DA Craft S Fagan AM Iwatsubo T Jack CR Jr Kaye J Montine TJ Park DC Reiman EM Rowe CC Siemers E Stern Y Yaffe K Carrillo MC Thies B Morrison-Bogorad M Wagster MV Phelps CH 贾建平(译) 郭起浩(译) 黄丽(译) 陆璐(译) 张逸驰(译) 邢怡(译) | 2012 | 中华神经科杂志2012，45，5： | 22 |
| 12 | 脑缺氧是影响严重颅脑创伤患者短期预后的独立危险因素(英文)显示文摘Background:Brain hypoxia(BH)can aggravate outcome after severe traumatic brain injury(TBI).Whether BH or reduced brain oxygen(Pbto2)is an independent outcome predictor or a marker of disease severity is not fully elucidated.Objective To analyze the relationship between Pbto2,intracranial pressure(ICP),and cerebral perfusion pressure(CPP)and to examine whether BH correlates with worse outcome independently of ICP and CPP.Methods We studied103patients | Oddo M Levine JM Mackenzie L Frangos S Feihl F Kasner SE Katsnelson M Pukenas B Macmurtrie E Maloney-Wilensky E Kofke WA Leroux PD | 2011 | 中华神经外科疾病研究杂志2011，10，5： | 21 |
| 13 | Epidural anesthesia improves pancreatic perfusion and decreases the severity of acute pancreatitis显示文摘AIM: To study the safety of epidural anesthesia(EA),its effect on pancreatic perfusion and the outcome of patients with acute pancreatitis(AP).METHODS: From 2005 to August 2010,patients with predicted severe AP [Ranson score ≥ 2,C-reactive protein > 100 or necrosis on computed tomography(CT)] were prospectively randomized to either a group receiving EA or a control group treated by patientcontrolled intravenous analgesia. Pain management was evaluated in the two groups every eight hours using the visual analog pain scale(VAS). Parameters for clinical severity such as length of hospital stay,use of antibiotics,admission to the intensive care unit,radiological/clinical complications and the need for surgical necrosectomy including biochemical data were recorded. A CT scan using a perfusion protocol was performed on admission and at 72 h to evaluate pancreatic blood flow. A significant variation in blood flow was defined as a 20% difference in pancreatic perfusion between admission and 72 h and was measured in the head,body and tail of the pancreas.RESULTS: We enrolled 35 patients. Thirteen were randomized to the EA group and 22 to the control group. There were no differences in demographic characteristics between the two groups. The Balthazar radiological severity score on admission was higher in the EA group than in the control group(mean score 4.15 ± 2.54 vs 3.38 ± 1.75,respectively,P = 0.347) and the median Ranson scores were 3.4 and 2.7 respectively(P = NS). The median duration of EA was 5.7 d,and no complications of the epidural procedure were reported. An improvement in perfusion of the pancreas was observed in 13/30(43%) of measurements in the EA group vs 2/27(7%) in the control group(P = 0.0025). Necrosectomy was performed in 1/13 patients in the EA group vs 4/22 patients in the control group(P = 0.63). The VAS improved during the first ten days in the EA group compared to the control group(0.2 vs 2.33,P = 0.034 at 10 d). Length of stay and mortality were not statistically different between the 2 groups(26 d vs 30 d,P = 0.65,and 0% for both respectively).CONCLUSION: Our study demonstrates that EA increases arterial perfusion of the pancreas and improves the clinical outcome of patients with AP. | Samira M Sadowski Axel Andres Philippe Morel Eduardo Schiffer Jean-Louis Frossard Alexandra Platon Pierre-Alexandre Poletti Leo Bühler | 2015 | World Journal of Gastroenterology2015，21，43： | 21 |
| 14 | Sharing Clinical Trial Data: A Proposal from the International Committee of Medical Journal Editors显示文摘The International Committee of Medical Journal Editors (ICMJE) believes that there is an ethical obligation to responsibly share data generated by interventional clinical trials because participants have put themselves at risk.In a growing consensus,many funders around the world-foundations,government agencies,and industry-now mandate data sharing.Here,we outline ICMJE's proposed requirements to help meet this obligation.We encourage feedback on the proposed requirements.Anyone can provide feedback at www.icmje.org by April 18,2016. | Darren B Taichman Joyce Backus Christopher Baethge Howard Bauchner Peter W de Leeuw Jeffrey M Drazen John Fletcher Frank Frizelle Irish Groves Abraham Haileamlak Astrid James Christine Laine Larry Peiperl Anja Pinborg Peush Sahni Si-Nan Wu | 2016 | Chinese Medical Journal2016，，2： | 20 |
| 15 | 广东龙窝花岗闪长质岩体的年代学、地球化学及岩石成因显示文摘龙窝岩体是南岭地区燕山早期具幔源组分贡献的花岗岩的典型代表,其主体岩性为花岗闪长岩,岩体中含有深色闪长质包体,锆石ELA-ICP-MS定年结果表明花岗闪长岩的形成年龄为169.1±2.5Ma,属中侏罗世岩浆活动的产物。地球化学特征上,该岩体铝弱过饱和(A/NKC=1.0~1.1),相对贫碱,富钾(K_2O/Na_2O=1.15~1.45),富轻稀土和大离子亲石元素(如Rb、Cs、Th、U),贫高场强元素(如Nb、Ti)。闪长质包体具有与寄主岩相似的矿物组合,但铁镁矿物含量及过渡族元素(V、CR、Co、Ni)丰度相对偏高,二者的主量和微量元素表现出混合成因的演化趋势。寄主岩与包体具有相近的Sr、Nd同位素组成,I_(Sr)和ε_(Nd)(t)值分别为0.70843~0.70995、-6.53~-8.89和0.70797~0.70882、-4.71~-9.24,均表现出壳幔混源花岗岩类岩石的特点。二元混合模拟计算显示寄主岩与包体成岩过程中地幔物质的混入比例分别为32.9%~40.4%和 31.8%~46.4%。通过对岩石产出构造背景及地质地球化学特征的综合分析,表明龙窝花岗闪长岩及其中的闪长质包体是在伸展-引张环境下,由幔源基性岩浆及其诱发的壳源长英质岩浆混合作用的产物。 | 邱检生 胡建 McInnes B I A 蒋少涌 徐夕生 Allen C M | 2004 | 岩石学报2004，20，6： | 19 |
| 16 | 联合应用MDM2和CDK4免疫组化标记有助于鉴别低级别骨肉瘤与其它骨原发性纤维骨性病变显示文摘低级别骨肉瘤是较为少见的恶性肿瘤,依据肿瘤原发位置与骨皮质的关系可分为两种亚型,即骨旁骨肉瘤和低级别中央型骨肉瘤。两者组织学形态相似,主要由轻到中度异型的梭形细胞和分化良好的网状新生骨小梁结构组成。 | Dujardin F Binh M B Bouvier C 孙琦 樊祥山 | 2011 | 临床与实验病理学杂志2011，27，12： | 19 |
| 17 | 等轴球晶凝固多相体系内热溶质对流、补缩流及晶粒运动的数值模拟 Ⅰ.三相流模型显示文摘基于Eulerian-Eulerian方法和体积元平均技术,建立了模拟等轴球晶凝固过程的液、固、气三相流模型.液、固两相处理成相互分离、相互扩散的介质,气相与液、固两相只存在热量及动量的相互作用,三相(凝固前)作为自由流体共享一个统一的压力场.分别求解三相的质量、动量、溶质、热焓守恒方程;相间的热量交换和摩擦拖拽以及液/固界面上的溶质再分配和凝固潜热释放,通过定义对应守恒方程的源项和交换项而加以考虑;另外,单独求解一个晶粒密度守恒方程.晶粒的形核生长(相变) 也加以模型化并体现在对应的源项中,模型中所用的密度定义为溶质与温度的函数,因此可综合考虑热溶质对流、晶粒运动及凝固收缩所引起的补缩流动.凝固过程的体积收缩及补缩流动将体现在气/液自由表面的波动上. | 王同敏 姚山 张兴国 金俊泽 M Wu A Ludwig B Pustal A Bührig-Polaczek | 2006 | 金属学报2006，42，6： | 18 |
| 18 | 利用ORYZA2000模型分析北京地区旱稻产量潜力及需水特征显示文摘在模型验证的基础上,利用ORYZA2000模型分析表明,北京地区旱稻产量潜力30年平均为8573kghm-2,变化范围为6747~11278kghm-2,年际间变异系数为16.3%。而雨养产量的多年平均值为4084kghm-2,变化范围223~8018kghm-2,年际间的变异系数高达51.1%。产量潜力与雨养产量之差表明北京地区旱稻尚有一定的增产潜力。旱稻全生育期需水量的多年平均值为713mm,年际间变异为8.5%。其中,出苗—穗分化阶段由于持续时间长,需水量最大,占全生育期的49.7%。全生育期的平均需水强度为5.3mmd-1,需水强度最大的时期为穗分化—开花阶段,平均为5.5mmd-1。北京地区生育期内的降水量不能完全满足旱稻的需水要求,50%的年份水分亏缺量在250mm以上,水分亏缺量多年平均值为226mm,年际间变异较大,变异系数高达81.4%。 | 薛昌颖 杨晓光 邓伟 张天一 闫伟兄 张秋平 肉孜阿基 赵俊芳 杨婕 Bouman B A M | 2007 | 作物学报2007，33，4： | 18 |
| 19 | Autophagy in mammalian cells显示文摘Autophagy is a regulated process for the degradation of cellular components that has been well conserved in eukaryotic cells. The discovery of autophagy-regulating proteins in yeast has been important in understanding this process. Although many parallels exist between fungi and mammals in the regulation and execution of autophagy, there are some important differences. The preautophagosomal structure found in yeast has not been identified in mammals, and it seems that there may be multiple origins for autophagosomes, including endoplasmic reticulum, plasma membrane and mitochondrial outer membrane. The maturation of the phagophore is largely dependent on 5'-AMP activated protein kinase and other factors that lead to the dephosphorylation of mammalian target of rapamycin. Once the process is initiated, the mammalian phagophore elongates and matures into an autophagosome by processes that are similar to those in yeast. Cargo selection is dependent on the ubiquitin conjugation of protein aggregates and organelles and recognition of these conjugates by autophagosomal receptors. Lysosomal degradation of cargo produces metabolites that can be recycled during stress. Autophagy is an impor-tant cellular safeguard during starvation in all eukaryotes; however, it may have more complicated, tissue specific roles in mammals. With certain exceptions, autophagy seems to be cytoprotective, and defects in the process have been associated with human disease. | Kadija Abounit Tiziano M Scarabelli Roy B McCauley | 2012 | World Journal of Biological Chemistry2012，3，1： | 18 |
| 20 | 纳秒、皮秒和飞秒激光脉冲对材料表面的改性(英文)显示文摘对基体材料镉镍铁合金600和多层TiAlN/TiN涂层的激光表面改性在基础研究和实际应用中有着很好的前景。本文观察了由超短脉冲(fs和ns)和短脉冲(ns)激光器引起的镉镍铁合金600和TiAlN/TiN镀层的表面变化。结果显示,3种激光都能使靶面发生形态改变,超短脉冲的破坏轮廓更为清晰。与ps激光脉冲相比,fs激光脉冲能产生更严重的破坏。与产生半球体形状的ps激光束相反,fs激光脉冲产生的破坏斑是圆锥形的。另外,ns脉冲辐照时热效应占支配地位,且所有的辐照都伴随着等离子体。 | TRTICAM S GAKOVIC B M RADAK B B BATANI D TARASENKO V F PETROVIC S STASIC J MILOVANOVIC D KRMPOT A JELENKOVIC B | 2011 | 光学精密工程2011，19，2： | 18 |
您所在的机构暂未开通此部分的功能，请联系管理员